Wellnex Life Limited - Q3 FY26 Quarterly Update and Appendix 4C

Wellnex Life

30/04/2026 07:30

RNS Number : 5696C

Wellnex Life Limited

30 April 2026

 

ASX/AIM Announcement         

                                                                                                                        30 April 2026

Quarterly Update and Appendix 4C - March 2026

HIGHLIGHTS

 

 

•     Milestone quarter Wellnex Life achieved its first quarter of positive operating cash flow since the current turnaround strategy commenced, marking a significant inflection point in the Company's ongoing progression

•     Customer cash receipts increased 30.8% to $6.67 million (Q2 FY26: $5.10 million), reflecting strong commercial momentum and improved working capital conversion across the Company's brand portfolio

•     Operating cash flow moved to positive $0.41 million (Q2 FY26: outflow of $0.16 million), a quarter-on-quarter improvement of $0.57 million driven by disciplined cost management

•     Staff costs declined 29% quarter-on-quarter to $0.75 million (Q2 FY26: $1.06 million), reflecting the tangible and structural benefits of the Company's ongoing cost reduction programme

•     Cost reduction strategy continued across advertising and marketing (down to $0.54 million from $0.62 million in the prior quarter) and administration, demonstrating broad-based operational efficiency gains

•     The Board remains firmly focused on delivering Q4 FY26 with revenue growth, margin improvement and cash generation as its core priorities

 

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is pleased to provide its quarterly operational and business update together with its Appendix 4C for the quarter ended 31 March 2026 (all figures unaudited). The March 2026 quarter represents a defining moment in Wellnex Life's turnaround, with the Company returning to positive operating cash flow for the first time since the current management team's strategy was implemented.

Momentum accelerates

Customer cash receipts for Q3 FY26 improved to $6.67 million, representing a 30.8% increase on the $5.10 million recorded in Q2 FY26. This strong uplift reflects genuine commercial momentum across Wellnex Life's core brand portfolio, including Pain Away, Wakey Wakey and Nighty Night, as well as continued improvement in the Company's working capital cycle and cash conversion. Year-to-date customer receipts stand at $16.31 million.

Revenue in Q3 FY26 declined compared to Q2 FY26 due, in part, to the cyclical nature of IP licensing as well as reduced investment, in the short term, in the Company's non-core brands, in particular marketing and advertising. Notwithstanding this, the Company is targeting stronger revenue growth in Q4 FY26, benefiting from more focussed marketing effort and typically higher activity across the business in Q4.

Revenue
Q3 FY26
Q2 FY26
% Change
Brands
$3.5 million
$3.8 million
-7.9%
IP Licensing
$1.6 million
$3.3 million
-51.5%
Total
$5.1 million
$7.1 million
-28.2%
Gross Profit
$1.5 million
$2.1 million
-28.6%

 

Operating cash flow turns positive

The Company delivered net operating cash flow of positive $0.41 million in Q3 FY26, compared to an outflow of $0.16 million in Q2 FY26 - a quarter-on-quarter improvement of $0.57 million. This positive result reflects the combined impact of accelerating customer receipts and the sustained cost discipline implemented across the organisation throughout FY26. The achievement of positive operating cash flow is a key milestone in the Company's turnaround and validates the strategy being executed by the Board and management team.

Structural cost reductions deliver results

The benefits of the Company's cost reduction programme are clearly evident in Q3 FY26results. Staff costs declined sharply to $0.75 million, down 29% from $1.06 million in Q2 FY26, reflecting a leaner, more efficient organisational structure. Advertising and marketing expenditure reduced to $0.54 million from $0.62 million, albeit with a short-term impact on revenue, while administration and corporate costs also declined. Product manufacturing and operating costs increased to $3.60 million (Q2 FY26: $2.51 million), consistent with the sales volumes recorded during the quarter and ongoing investment in supporting the Company's core product lines.

Related party payments

Payments of $0.32 million were made to related parties during the quarter. These payments relate to directors' fees, executive remuneration and associated costs incurred in the ordinary course of business.

Outlook

The Board enters Q4 FY26 with confidence, building on the positive operating cash flow result and a targeted revenue trajectory in Q4 FY26. Management's focus for the final quarter of FY26, and beyond, is on sustaining revenue growth, continuing to improve gross margins through the Company's owned-brand strategy, and further strengthening the balance sheet. The Company believes it is well-positioned to deliver a strong finish to FY26 and to build on the turnaround foundations established during the year.

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

--- END ---

 

 

 

 

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)                            

Eric Jiang                                                                               

Interim Executive Chairman                                                              

E: eric.j@wellnexlife.com.au    

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

 

James Harris / Richard Johnson                                         Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint Broker)                                 swykeham@oranacorp.com

Sebastian Wykeham    

 

S.P. Angel Corporate Finance LLP (Joint Broker)           Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

 

To learn more, please visit: https://wellnexlife.com.au/

 

 

 

 

 

 

 

 

 

 

Appendix 4C

Quarterly cash flow report for entities

subject to Listing Rule 4.7B

Name of entity
WELLNEX LIFE LIMITED
ABN
Quarter ended ("current quarter")
77 150 759 363
31 March 2026

 

Consolidated statement of cash flows
Current quarter $A'000
Year to date
(9 months)
 $A'000
1.
Cash flows from operating activities
6,672
16,309
1.1
Receipts from customers
1.2
Payments for
(35)
(295)
(a) research and development
(b) product manufacturing and operating costs
(3,599)
(10,696)
(c) advertising and marketing
(539)
(1,967)
(d) leased assets
(e) staff costs
(745)
(2,689)
(f) administration and corporate costs
(532)
(1,800)
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
0
0
1.5
Interest and other costs of finance paid
(431)
(781)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
-
1.8
Other (GST refund/(paid))
(379)
(811)
1.9
Net cash from / (used in) operating activities
412
(2,730)
2.
Cash flows from investing activities
-
-
2.1
Payments to acquire or for:
(a) entities
(b) businesses
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
(f) other non-current assets
-
-
2.2
Proceeds from disposal of:
-
-
(a) entities
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f) other non-current assets
-
-
2.3
Loan repayment from other entity
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (cash acquired from CBDG Administration)
-
2.6
Net cash from / (used in) investing activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities (excluding convertible debt securities)
3.2
Proceeds from issue of convertible debt securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of equity securities or convertible debt securities
22
(1,128)
3.5
Proceeds from borrowings
3,295
14,972
3.6
Repayment of borrowings
(4,311)
(11,218)
3.7
Transaction costs related to loans and borrowings
(176)
(176)
3.8
Share applications to be refunded
-
-
3.9
Other (repayment of lease liabilities)
-
-
3.10
Net cash from / (used in) financing activities
(1,170)
2,450
4.
Net increase / (decrease) in cash and cash equivalents for the period
975
497
4.1
Cash and cash equivalents at beginning of period
4.2
Net cash from / (used in) operating activities (item 1.9 above)
412
(2,730)
4.3
Net cash from / (used in) investing activities (item 2.6 above)
4.4
Net cash from / (used in) financing activities (item 3.10 above)
(1,170)
2,450
4.5
Effect of movement in exchange rates on cash held
-
(1)
4.6
Cash and cash equivalents at end of period
217
217


 

5.
Reconciliation of cash and cash equivalents
 at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts
Current quarter
 $A'000
Previous quarter
 $A'000
5.1
Bank balances
217
975
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (funds held in trust)
-
-
5.5
Cash and cash equivalents at end of quarter (should equal item 4.6 above)
217
975


 

6.
Payments to related parties of the entity and their associates
Current quarter
 $A'000
6.1
Aggregate amount of payments to related parties and their associates included in item 1
317
6.2
Aggregate amount of payments to related parties and their associates included in item 2
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

 

7.
Financing facilitiesNote: the term "facility' includes all forms of financing arrangements available to the entity.
Add notes as necessary for an understanding of the sources of finance available to the entity.
Total facility amount at quarter end
 $A'000
Amount drawn at quarter end
 $A'000
7.1
Loan facilities
9,250
(6,103)
7.2
Credit standby arrangements
-
-
7.3
Other (Director's loan)
2,525
(2,525)
7.4
Total financing facilities
11,775
(8,628)
7.5
Unused financing facilities available at quarter end
3,147
7.6
Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.
1. Secured Revolving Trade and Debtor Facility with Scottish Pacific of $3.8 million
Interest Rate: BBSY plus 6.8%.
2. Secured loan facility with Reach Wholesale of up to $5.35 million at 14% per annum expiring August 2027. The amount shown in Section 7 is for the full amount drawn down ($5.35 million) at the close of the period

 

8.
Estimated cash available for future operating activities
$A'000
8.1
Net cash from / (used in) operating activities (item 1.9)
412
8.2
Cash and cash equivalents at quarter end (item 4.6)
217
8.3
Unused finance facilities available at quarter end (item 7.5)
3,147
8.4
Total available funding (item 8.2 + item 8.3)
3,363
8.5
Estimated quarters of funding available (item 8.4 divided by item 8.1)
N/A
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

 

Compliance statement

1          This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2          This statement gives a true and fair view of the matters disclosed.

 

                                    30 April 2026

Date:                ...................................................................................

 

                                    The Board of Directors

Authorised by: ...................................................................................

(Name of body or officer authorising release - see note 4)

 

Notes

1.          This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2.          If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3.          Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4.          If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee - eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5.          If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
UPDURANRNSUSORR